International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 126-129
EFFICIENCY OF CISPLATIN AND EPIRUBICIN CHEMOTHERAPY REGIMEN IN PRIMARY UNKNOWN METASTATIC ADENOCARCINOMA CASES
HASAN ÜSTÜN1, UĞUR YILMAZ1, SABRİ BARUTCA1, TUĞBA ULAŞ1, CANER ÇAVDAR1, ERDENER ÖZER1, MEHMET ALAKAVUKLAR1
Kocaeli Üniversitesi Tıp Fakültesi Dahiliye Anabilim Dalı, İzmit
Keywords: primary unknown metastatic adenocarcinoma, chemotherapy, cisplatin, epirubicin
There is not any standard chemotherapy for primary unknown metastatic carcinoma. In this study, we aimed to determine efficiency of cisplatin and epirubicin chemotherapy regimen in patients with primary unknown metastatic adenocarcinoma. The chemotherapy regimen was given to 18 patients with primary unknown metastatic adenocarcinoma. In these patients, 1 (5%) complete response and 3 (17%) partial responses were seen. The median survival time of all patients was found as 4.5±2.77 (min-max, 2-13) month. These results were inferior to the literature results. We concluded that while our all cases are adenocarcinoma, some of the cases are poorly differentiated carcinoma in the literature may be the cause of this difference. The new chemotherapy regimens should be improved for primary unknown metastatic carcinoma cases and tested in larger scaled patient numbers.
HASAN ÜSTÜN1, UĞUR YILMAZ1, SABRİ BARUTCA1, TUĞBA ULAŞ1, CANER ÇAVDAR1, ERDENER ÖZER1, MEHMET ALAKAVUKLAR1
Kocaeli Üniversitesi Tıp Fakültesi Dahiliye Anabilim Dalı, İzmit
Keywords: primary unknown metastatic adenocarcinoma, chemotherapy, cisplatin, epirubicin
There is not any standard chemotherapy for primary unknown metastatic carcinoma. In this study, we aimed to determine efficiency of cisplatin and epirubicin chemotherapy regimen in patients with primary unknown metastatic adenocarcinoma. The chemotherapy regimen was given to 18 patients with primary unknown metastatic adenocarcinoma. In these patients, 1 (5%) complete response and 3 (17%) partial responses were seen. The median survival time of all patients was found as 4.5±2.77 (min-max, 2-13) month. These results were inferior to the literature results. We concluded that while our all cases are adenocarcinoma, some of the cases are poorly differentiated carcinoma in the literature may be the cause of this difference. The new chemotherapy regimens should be improved for primary unknown metastatic carcinoma cases and tested in larger scaled patient numbers.